<i>APOE</i> ‐associated disease risk and sex‐specific effects in Egyptian Alzheimer's disease: an exploratory study
Mai Othman(American University in Cairo), Mohamed Salama(Mansoura University), Samer Salama(Mansoura University), Nourelhoda A. Haridy(Assiut University), Noha Abo Elftoh(Assiut University), Mohamed H. Yousef(American University in Cairo), Gellan K. Ahmed(Assiut University), Samir Shamma(American University in Cairo), Eman Khedr(Assiut University), Agsha Atputhavadivel(National Hospital for Neurology and Neurosurgery), Ahmed Qayaty(Beni-Suef University), Muhammad Abdelshafi(Mansoura University Hospital), Shimaa Heikal(American University in Cairo), Mie Rizig(MRC Prion Unit), Hany I. Hassanin(Ain Shams University), Nesma G. Elsheikh(Ain Shams University), Sara El Farrash(Mansoura University), Heba M. Tawfik(Ain Shams University), Noha A. Yousri(Alexandria University), Amna Ibrahim(Beni-Suef University), Eman M. Ali(Beni-Suef University), Gharib Fawi(Sohag University)
Alzheimer s & Dementia Translational Research & Clinical Interventions
April 1, 2026
Cited by 0
Related Papers
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline <i>BRCA</i>-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
|Clinical Cancer Research|2015|532
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
|Clinical Cancer Research|2015|377
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
|Clinical Cancer Research|2014|350
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
|Journal of Clinical Oncology|2019|348